High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone-Reference-Cited by-同舟云学术

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

Published:2013-04-09 Issue:5 Volume:161 Page:695-700
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Heintel Daniel¹,Rocci Alberto²,Ludwig Heinz¹,Bolomsky Arnold¹,Caltagirone Simona²,Schreder Martin¹,Pfeifer Sabine¹,Gisslinger Heinz³,Zojer Niklas¹,Jäger Ulrich³,Palumbo Antonio²

Affiliation:

1. Department of Internal Medicine I; Center for Oncology and Haematology; Wilhelminenspital; Vienna; Austria

2. Divisione di Ematologia dell'Università di Torino; Azienda Ospedaliera S. Giovanni Battista; Ospedale Molinette; Torino; Italy

3. Division of Haematology and Haemostaseology; Department of Medicine I; Medical University of Vienna (MUW); Vienna; Austria

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12338/fullpdf

Reference26 articles.

1. Lenalidomide and thalidomide: mechanisms of action-similarities and differences;Anderson;Seminars in Hematology,2005

2. Evidence of a role for activation of Wnt/ß-catenin signaling in the resistance of plasma cells to lenalidomide;Bjorklund;The Journal of Biological Chemistry,2011

3. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance;Broyl;Blood,2012

4. What is the functional role of the thalidomide binding protein cereblon?;Chang;International Journal of Biochemistry and Molecular Biology,2011

5. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma;Dimopoulos;The New England Journal of Medicine,2007

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors and PROTACs of CDK2: challenges and opportunities;Expert Opinion on Drug Discovery;2024-07-12

2. Targeting the ubiquitin pathway in lymphoid malignancies;Cancer Letters;2024-07

3. The emerging role of targeted protein degradation to treat and study cancer;The Journal of Pathology;2024-06-17

4. Decreased RNA‐binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide;British Journal of Haematology;2024-04-29

5. Evaluation of cereblon expression in gastrointestinal tract tumors;2024-04-19